JP2023115348A5 - - Google Patents

Download PDF

Info

Publication number
JP2023115348A5
JP2023115348A5 JP2023108132A JP2023108132A JP2023115348A5 JP 2023115348 A5 JP2023115348 A5 JP 2023115348A5 JP 2023108132 A JP2023108132 A JP 2023108132A JP 2023108132 A JP2023108132 A JP 2023108132A JP 2023115348 A5 JP2023115348 A5 JP 2023115348A5
Authority
JP
Japan
Prior art keywords
polynucleotide
seq
identity
nucleotide sequence
polynucleotide according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023108132A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023115348A (ja
JP7631425B2 (ja
Filing date
Publication date
Priority claimed from JP2020132079A external-priority patent/JP7069258B2/ja
Application filed filed Critical
Publication of JP2023115348A publication Critical patent/JP2023115348A/ja
Publication of JP2023115348A5 publication Critical patent/JP2023115348A5/ja
Application granted granted Critical
Publication of JP7631425B2 publication Critical patent/JP7631425B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023108132A 2015-11-13 2023-06-30 組換えｆｖｉｉｉ変異型をコードする血友病ａ遺伝子治療用高発現ウイルスベクター Active JP7631425B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562255317P 2015-11-13 2015-11-13
US62/255,317 2015-11-13
JP2020132079A JP7069258B2 (ja) 2015-11-13 2020-08-04 組換えｆｖｉｉｉ変異型をコードする血友病ａ遺伝子治療用高発現ウイルスベクター
JP2022075864A JP7307836B2 (ja) 2015-11-13 2022-05-02 組換えｆｖｉｉｉ変異型をコードする血友病ａ遺伝子治療用高発現ウイルスベクター

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022075864A Division JP7307836B2 (ja) 2015-11-13 2022-05-02 組換えｆｖｉｉｉ変異型をコードする血友病ａ遺伝子治療用高発現ウイルスベクター

Publications (3)

Publication Number Publication Date
JP2023115348A JP2023115348A (ja) 2023-08-18
JP2023115348A5 true JP2023115348A5 (enExample) 2023-11-17
JP7631425B2 JP7631425B2 (ja) 2025-02-18

Family

ID=57539605

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018524747A Expired - Fee Related JP6768798B2 (ja) 2015-11-13 2016-11-11 組換えｆｖｉｉｉ変異型をコードする血友病ａ遺伝子治療用高発現ウイルスベクター
JP2020132079A Active JP7069258B2 (ja) 2015-11-13 2020-08-04 組換えｆｖｉｉｉ変異型をコードする血友病ａ遺伝子治療用高発現ウイルスベクター
JP2022075864A Active JP7307836B2 (ja) 2015-11-13 2022-05-02 組換えｆｖｉｉｉ変異型をコードする血友病ａ遺伝子治療用高発現ウイルスベクター
JP2023108132A Active JP7631425B2 (ja) 2015-11-13 2023-06-30 組換えｆｖｉｉｉ変異型をコードする血友病ａ遺伝子治療用高発現ウイルスベクター

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2018524747A Expired - Fee Related JP6768798B2 (ja) 2015-11-13 2016-11-11 組換えｆｖｉｉｉ変異型をコードする血友病ａ遺伝子治療用高発現ウイルスベクター
JP2020132079A Active JP7069258B2 (ja) 2015-11-13 2020-08-04 組換えｆｖｉｉｉ変異型をコードする血友病ａ遺伝子治療用高発現ウイルスベクター
JP2022075864A Active JP7307836B2 (ja) 2015-11-13 2022-05-02 組換えｆｖｉｉｉ変異型をコードする血友病ａ遺伝子治療用高発現ウイルスベクター

Country Status (18)

Country Link
US (4) US10189888B2 (enExample)
EP (1) EP3374387A1 (enExample)
JP (4) JP6768798B2 (enExample)
KR (2) KR20230008256A (enExample)
CN (3) CN108884145B (enExample)
AU (4) AU2016353353B2 (enExample)
BR (1) BR112018009717B1 (enExample)
CA (1) CA3005334A1 (enExample)
CL (1) CL2018001299A1 (enExample)
CO (1) CO2018005377A2 (enExample)
EA (2) EA038288B1 (enExample)
IL (3) IL305526A (enExample)
MX (1) MX2018005982A (enExample)
MY (2) MY190067A (enExample)
SG (2) SG10202106307UA (enExample)
TW (3) TW202302627A (enExample)
WO (1) WO2017083762A1 (enExample)
ZA (3) ZA201803443B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10143760B2 (en) 2015-10-28 2018-12-04 Sangamo Therapeutics, Inc. Liver-specific constructs, factor VIII expression cassettes and methods of use thereof
CN108884145B (zh) 2015-11-13 2023-08-22 武田药品工业株式会社 用于血友病a的基因治疗的具有增加的表达的编码重组fviii变体的病毒载体
KR102404550B1 (ko) * 2015-11-13 2022-05-31 다케다 야쿠힌 고교 가부시키가이샤 A형 혈우병의 유전자 요법을 위한 증가된 발현을 갖는 재조합 fviii 변이체를 인코딩하는 바이러스 벡터
PE20181922A1 (es) * 2016-04-15 2018-12-11 Univ Pennsylvania Terapia genica para tratar la hemofilia a
US11191847B2 (en) 2016-04-15 2021-12-07 The Trustees Of The University Of Pennsylvania Gene therapy for treating hemophilia B
CN110300591A (zh) 2016-11-04 2019-10-01 百深公司 腺相关病毒制剂
KR20200057051A (ko) * 2017-09-27 2020-05-25 시질론 테라퓨틱스, 인크. 활성 세포를 포함하는 방법, 조성물 및 이식 가능한 요소
MA49923A (fr) * 2017-10-02 2020-06-24 Res Inst Nationwide Childrens Hospital Système de déciblage de miarn pour interférence spécifique d'un tissu
KR102105145B1 (ko) * 2017-10-13 2020-05-13 영남대학교 산학협력단 촬영 장치 및 용기
KR101952102B1 (ko) * 2017-12-07 2019-02-26 주식회사 지앤피바이오사이언스 단백질 발현량이 증대된 인자 ⅷ 변이체 발현벡터
US12091675B2 (en) * 2018-07-16 2024-09-17 Takeda Pharmaceutical Company Limited Gene therapy of hemophilia a using viral vectors encoding recombinant FVIII variants with increased expression
AU2019314513B2 (en) * 2018-08-03 2026-04-30 Sangamo Therapeutics, Inc. Improved clinical parameters by expression of factor viii
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
GB201813528D0 (en) 2018-08-20 2018-10-03 Ucl Business Plc Factor IX encoding nucleotides
TWI851647B (zh) * 2019-01-16 2024-08-11 日商武田藥品工業股份有限公司 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
SG11202108357PA (en) 2019-02-15 2021-08-30 Crispr Therapeutics Ag Gene editing for hemophilia a with improved factor viii expression
BR112021015776A2 (pt) * 2019-06-05 2021-11-09 Bayer Healthcare Llc Edição de gene para hemofilia a com expressão de fator viii melhorada
CN114375205A (zh) * 2019-06-20 2022-04-19 武田药品工业株式会社 用基于病毒的基因疗法进行治疗的方法
WO2021084276A2 (en) * 2019-11-01 2021-05-06 Freeline Therapeutics Limited Factor viii construct
CN114981299A (zh) * 2019-12-12 2022-08-30 武田药品工业株式会社 使用编码具有增加的表达的重组fviii变体的病毒载体的a型血友病的基因疗法
WO2022211604A1 (ko) * 2021-04-02 2022-10-06 연세대학교 산학협력단 Fe-fviii 변이 유전자로 교정된 줄기세포, 이로부터 분화된 내피 세포 및 이를 포함하는 혈우병 예방 또는 치료용 약제학적 조성물
KR102421131B1 (ko) * 2021-05-28 2022-07-15 알엔에이진(주) 세포내에서 장시간동안 존재할 수 있는 외부 도입 mRNA를 선별하는 방법
CN118638211A (zh) * 2021-11-25 2024-09-13 四川至善唯新生物科技有限公司 基因工程改造获得的分泌能力和凝血活性增强的人类八因子
AU2023261338A1 (en) * 2022-04-28 2024-11-21 Joint Stock Company "Biocad" Codon-optimized nucleic acid encoding the fviii-bdd
CN115948408A (zh) * 2022-09-23 2023-04-11 上海信致医药科技有限公司 改进的人凝血因子viii基因表达盒及其应用
EP4680196A1 (en) 2023-03-14 2026-01-21 Sigilon Therapeutics, Inc. Hydrogel capsules comprising covalently photocrosslinked polysaccharides and islet cells
WO2025008774A1 (en) 2023-07-05 2025-01-09 Takeda Pharmaceutical Company Limited Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
WO2025180508A1 (en) * 2024-02-29 2025-09-04 Shanghai Vitalgen Biopharma Co., Ltd. Human factor viii variant expression cassettes and uses thereof for treating hemophilia a

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
MX9203440A (es) 1985-04-12 1992-07-01 Genetics Inst Proteinas procoagulantes novedosas.
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5595886A (en) 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US5543502A (en) 1986-06-24 1996-08-06 Novo Nordisk A/S Process for producing a coagulation active complex of factor VIII fragments
US6060447A (en) 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
IE69026B1 (en) 1987-06-12 1996-08-07 Immuno Ag Novel proteins with factor VIII activity process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
FR2619314B1 (fr) 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
WO1994029471A1 (en) 1993-06-10 1994-12-22 Genetic Therapy, Inc. Adenoviral vectors for treatment of hemophilia
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
US6818439B1 (en) 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
US5952198A (en) * 1995-05-04 1999-09-14 Bayer Corporation Production of recombinant Factor VIII in the presence of liposome-like substances of mixed composition
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US6458563B1 (en) 1996-06-26 2002-10-01 Emory University Modified factor VIII
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6924365B1 (en) 1998-09-29 2005-08-02 Transkaryotic Therapies, Inc. Optimized messenger RNA
US6200560B1 (en) 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
US6221349B1 (en) * 1998-10-20 2001-04-24 Avigen, Inc. Adeno-associated vectors for expression of factor VIII by target cells
US20060099685A1 (en) 1999-04-15 2006-05-11 Yallop Christopher A Recombinant expression of factor VIII in human cells
CN1179976C (zh) * 2000-12-29 2004-12-15 中国科学院上海生物化学研究所 产生凝血因子ⅷ的生产方法和宿主细胞
DE60230456D1 (de) 2001-10-05 2009-01-29 Expression Therapeutics Llc Faktor-viii-polypeptide auf hohem expressionsnivea und verwendungsverfahren
DK2359869T3 (en) 2001-12-17 2019-04-15 Univ Pennsylvania Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
WO2005017149A1 (en) * 2003-06-03 2005-02-24 Cell Genesys, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
US7943374B2 (en) 2005-08-21 2011-05-17 Markus Hildinger Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb
CN101511373B (zh) 2006-06-19 2015-12-09 阿斯克肋匹奥生物制药公司 用于基因治疗的修饰的因子ⅷ和因子ⅸ基因和载体
WO2008077616A1 (en) 2006-12-22 2008-07-03 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
KR100959454B1 (ko) 2007-12-10 2010-05-25 주식회사 동부하이텍 반도체 소자 및 그 제조 방법
US9617548B2 (en) 2008-04-22 2017-04-11 Vib Vzw Liver-specific nucleic acid regulatory elements and methods and use thereof
ES2427627T3 (es) 2009-04-06 2013-10-31 Novo Nordisk A/S Entrega dirigida de proteínas de Factor VIII a plaquetas
GB0911870D0 (en) 2009-07-08 2009-08-19 Ucl Business Plc Optimised coding sequence and promoter
PT2591006T (pt) 2010-07-09 2019-07-29 Bioverativ Therapeutics Inc Moléculas de cadeia simples processáveis e polipéptidos preparados utilizando as mesmas
US20130017997A1 (en) 2010-08-19 2013-01-17 Amunix Operating Inc. Factor VIII Compositions and Methods of Making and Using Same
EA028914B1 (ru) 2011-07-25 2018-01-31 Байоджен Хемофилия Инк. Исследования для мониторинга нарушений свертываемости крови
EA038705B1 (ru) * 2012-01-12 2021-10-07 Биовератив Терапьютикс Инк. Способы снижения иммуногенности фактора свёртывания крови viii у пациентов, получающих лечение фактором viii
HRP20191920T1 (hr) * 2012-01-12 2020-01-10 Bioverativ Therapeutics Inc. Kimerni polipeptidi faktora viii i njihova uporaba
CN111548418A (zh) * 2012-02-15 2020-08-18 比奥贝拉蒂治疗公司 因子viii组合物及其制备和使用方法
BR112014020325A2 (pt) 2012-02-17 2017-08-08 Childrens Hospital Philadelphia composições de vetor do aav e métodos para a transferência de gene para as células, órgãos e tecidos
CN104411338A (zh) * 2012-04-02 2015-03-11 现代治疗公司 用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸
GB201210357D0 (en) * 2012-06-12 2012-07-25 Ucl Business Plc Factor VIII sequences
WO2014008172A2 (en) 2012-07-03 2014-01-09 Expression Therapeutics, Llc High yield suspension cell line, system and method for making same
EP3513802B1 (en) 2012-10-26 2023-11-29 Vrije Universiteit Brussel Vector for liver-directed gene therapy of hemophilia and methods and use thereof
DK2911687T3 (da) 2012-10-26 2019-05-13 Univ Brussel Vrije Vektor til levermålrettet genterapi af hæmofili og fremgangsmåder og anvendelse deraf
RS61387B2 (sr) 2013-02-15 2024-06-28 Bioverativ Therapeutics Inc Gen optimizovanog faktora viii
AU2014237111B2 (en) 2013-03-15 2018-06-21 Bayer Healthcare Llc Recombinant factor VIII formulations
HRP20210031T1 (hr) 2013-06-24 2021-05-14 Weidong, Xiao Pripravci i metode mutantskog faktora viii
ES2813698T3 (es) * 2013-09-12 2021-03-24 Biomarin Pharm Inc Vectores de AAV que comprenden un gen que codifica el factor VIII
SG11201701033QA (en) 2014-08-13 2017-03-30 Philadelphia Children Hospital An improved expression cassette for packaging and expression of variant factor viii for the treatment of hemostasis disorders
KR102554850B1 (ko) * 2015-02-06 2023-07-13 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 최적화된 인간 응고 인자 viii 유전자 발현 카세트 및 그의 용도
JP6879486B2 (ja) 2015-03-17 2021-06-02 フリーイェ・ユニヴェルシテイト・ブリュッセルＶｒｉｊｅ Ｕｎｉｖｅｒｓｉｅｉｔ Ｂｒｕｓｓｅｌ Ｆｖｉｉｉおよびｆｉｘ用の最適化された肝臓特異的発現系
CN108884145B (zh) 2015-11-13 2023-08-22 武田药品工业株式会社 用于血友病a的基因治疗的具有增加的表达的编码重组fviii变体的病毒载体

Similar Documents

Publication Publication Date Title
JP2018537087A5 (enExample)
JP2018537089A5 (enExample)
JP2020520662A5 (enExample)
JP2012532601A5 (enExample)
JP2019509037A5 (enExample)
JP2023518596A5 (enExample)
JP2019506166A5 (enExample)
JP2017521074A5 (enExample)
JP2022505877A5 (enExample)
IL294059A (en) Mutant rsv f protein and its use
JP2024508683A5 (enExample)
JP2022176933A5 (enExample)
JP2024515827A5 (enExample)
JP5545209B2 (ja) 免疫原性を有する物質
JP2002539781A5 (enExample)
JP2020509770A5 (enExample)
WO2009141434A4 (en) Expression vector encoding alphavirus replicase and the use thereof as immunological adjuvant
CN101463089B (zh) 人血清白蛋白-干扰素融合蛋白及其编码基因与应用
CN103936840A (zh) 重组的人乳头瘤病毒33型l1蛋白及其用途
JP2006511212A5 (enExample)
US9861681B2 (en) Therapeutic compositions for neutralizing type I interferons, and methods of use
Zhu et al. Inter-chain disulfide bond improved protein trans-splicing increases plasma coagulation activity in C57BL/6 mice following portal vein FVIII gene delivery by dual vectors
JP2020530453A5 (enExample)
CN103819543B (zh) 重组的人乳头瘤病毒6型l1蛋白及其用途
TWI293957B (en) A superantigen fusion protein and the use thereof